FDA-cleared profile

SubtleHD (1.x)

Subtle Medical, Inc. · MRI · FDA-cleared (510(k))

Authorized purpose: MRI image enhancement through noise reduction and sharpening for clinical image review.

Clinical role
Post-processing image enhancement
Images and patients
MRI · Whole Body
Key limitation
Keep in mind: Produces enhanced images, not diagnostic findings or disease classifications. Radiologists retain responsibility for interpreting the images.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: MRI image enhancement through noise reduction and sharpening for clinical image review.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Whole Body Input: Standard-of-care or accelerated DICOM MRI, including 2D/3D, contrast and noncontrast images of all body parts across the described protocols and 0.25-3 T field strengths.
  • Who uses it?Intended users: Radiologists and technologists in imaging centers, clinics or hospitals.
  • What does the software produce?Output: Noise-reduced, sharpened DICOM images sent to a configured PACS, MR device or workstation; enhanced and original images coexist.
  • What is its most important limitation?Key limitation: Produces enhanced images, not diagnostic findings or disease classifications. Radiologists retain responsibility for interpreting the images.

Clinical takeaway. Clinical role: MRI image enhancement through noise reduction and sharpening for clinical image review.

Evidence takeaway. Evidence from the reviewed source record: The regulatory summary includes a 97-sample standalone comparison and a separate 410-image reader study assessing enhancement. A later vendor-authored study evaluates downstream classification using enhanced images and is contextual only.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
MRI image enhancement through noise reduction and sharpening for clinical image review.
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Post-processing image enhancement
  • Exact FDA submission
  • Checked 2026-09-05
Required input
Standard-of-care or accelerated DICOM MRI, including 2D/3D, contrast and noncontrast images of all body parts across the described protocols and 0.25-3 T field strengths.
  • Exact FDA submission
  • Checked 2026-09-05
Output and clinician action
Noise-reduced, sharpened DICOM images sent to a configured PACS, MR device or workstation; enhanced and original images coexist.
  • Exact FDA submission
  • Checked 2026-09-05
Care setting
Adult and Pediatric
  • Exact FDA submission
  • Checked 2026-09-01

Baseline patient-population label retained; the FDA material defines the acquisition scope.

Intended users
Radiologists and technologists in imaging centers, clinics or hospitals.
  • Exact FDA submission
  • Checked 2026-09-05
Limitations
Produces enhanced images, not diagnostic findings or disease classifications. Radiologists retain responsibility for interpreting the images.
  • Exact FDA submission
  • Checked 2026-09-05
Evidence summary
The regulatory summary includes a 97-sample standalone comparison and a separate 410-image reader study assessing enhancement. A later vendor-authored study evaluates downstream classification using enhanced images and is contextual only.
  • Exact FDA submission
  • Checked 2026-09-05

Baseline study counts retained with separate study units; no pooled unique-patient total is asserted.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The regulatory summary includes a 97-sample standalone comparison and a separate 410-image reader study assessing enhancement. A later vendor-authored study evaluates downstream classification using enhanced images and is contextual only.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

Baseline study counts retained with separate study units; no pooled unique-patient total is asserted.

Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

No exact-release disease-detection sensitivity is established by the reviewed enhancement studies.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

No exact-release disease-detection specificity is established by the reviewed enhancement studies.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K243250 standalone enhancement comparison

  • DesignRetrospective standalone image-quality validation
  • Population97 MRI samples in the standalone comparison described in the summary
  • Scopeexact submission
  • Tested versionSubtleHD 1.x
  • Samplen=97
  • IndependenceSponsor or vendor study

K243250

K243250 MRI reader study

  • DesignReader comparison of standard and enhanced MRI
  • Population410 images across body parts and protocols
  • Scopeexact submission
  • Tested versionSubtleHD 1.x
  • Samplen=410
  • IndependenceSponsor or vendor study

K243250

Image count, not a verified unique-patient total.

Deep Learning-Based Enhancement of Already Diagnostic-Quality MRI for Alzheimer's Disease Classification: Effects on Model Performance and Training Data Requirements

  • DesignRetrospective downstream machine-learning classification study
  • Population2293 ADNI brain MRI scans split into training, validation and internal testing; 270 NACC scans for external testing, 1.5 T 3D T1 gradient echo
  • Scopeproduct family
  • Tested versionSubtleHD; software release not established in the reviewed abstract
  • Samplen=2293
  • IndependenceSponsor or vendor study

PMID:42593101 · DOI:10.1002/jmri.70507

Several authors are affiliated with Subtle Medical. ResNet34/DenseNet121, not SubtleHD itself, performed Alzheimer/MCI/normal classification. No diagnostic indication or numeric accuracy is transferred to K243250.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-06

Downloaded exact-ID recall packet contained zero records; this limited result does not establish absence of recall or safety information.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Standard-of-care or accelerated DICOM MRI, including 2D/3D, contrast and noncontrast images of all body parts across the described protocols and 0.25-3 T field strengths.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · SubtleHD (1.x): K243250 clearance and summary

  2. Routing

    Source context, not route validation: Background processing without an end-user image-viewing UI; configuration through files, environment settings or series descriptions. DICOM destinations are specified by AE title and IP address.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-05 · SubtleHD (1.x): K243250 clearance and summary

  3. AI processing

    Source context, not route validation: The exact FDA package describes SubtleHD as a software package with no user interface that operates on a virtual machine. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Software package Same Same Same Characteristics Operates on a virtual machine" … "As it only processes images for the end user, the device has no user interface.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · SubtleHD (1.x): K243250 clearance and summary

  4. Returned objects

    Source context, not route validation: Noise-reduced, sharpened DICOM images sent to a configured PACS, MR device or workstation; enhanced and original images coexist.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-05 · SubtleHD (1.x): K243250 clearance and summary

  5. Viewer/worklist/report

    Unresolved route: Noise-reduced, sharpened DICOM images sent to a configured PACS, MR device or workstation; enhanced and original images coexist.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-05 · SubtleHD (1.x): K243250 clearance and summary

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes SubtleHD as a software package with no user interface that operates on a virtual machine. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Software package Same Same Same Characteristics Operates on a virtual machine" … "As it only processes images for the end user, the device has no user interface.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
Background processing without an end-user image-viewing UI; configuration through files, environment settings or series descriptions. DICOM destinations are specified by AE title and IP address.
  • Exact FDA submission
  • Checked 2026-09-05
Security
Subtle Medical's current compliance page lists an annual SOC 2 Type II + HIPAA security audit, and ISO 13485:2016 (valid until 2027-07-12) and ISO/IEC 42001:2023 (valid until 2028-07-17) certificates. The page gives no audit period or report scope, and the SOC 2 report was not read.
  • Vendor-wide
  • Checked 2026-10-25

Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.

Background DICOM routing

Processes DICOM images and returns enhanced images to configured AE-title/IP destinations while retaining original images.

exact submission · checked 2026-09-05

Current scanner examples

Vendor provides MR enhancement examples by scanner manufacturer and body part; these are family context, not an exact-release compatibility matrix.

product family · checked 2026-09-05
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243250
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Anatomy
Whole Body
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-02-12
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-05Last searched
21Fields reviewed
11Source classes checked
2Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

42608377 is editorial metadata, excluded as primary performance evidence. 42593101 abstract reviewed and retained as vendor-associated family study of downstream classification; exact release unverified. The current discovery snapshot contains 2 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, peer reviewed literature, stored candidate metadata, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission

    Current marketing offers a demo and operational-benefit examples, not a verified 1.x license/implementation price.

  • Pricing model: Not verified - checked 2026-09-05 - Exact FDA submission

    Standalone versus suite licensing and ongoing service terms require a quote.

  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "SubtleHD reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-05 - Exact FDA submission

    Version-specific onboarding content, competency assessment and training costs were not established.

  • Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission

    Current clinical-quality monitoring and upgrade acceptance procedures require confirmation.

9 sources - 3 history items

Source ledger

  1. SubtleHD (1.x): K243250 clearance and summary

    U.S. Food and Drug Administration - Accessed 2026-09-05

    Scope: purpose, clinicalUse, modality, anatomy, input, output, deployment, integration, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. SubtleHD (1.x) model card (K243250)

    American College of Radiology - Published 2026-07-20 - Accessed 2026-09-01

    Scope: purpose, modality, intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. SubtleHD(MR) product page

    Subtle Medical - Accessed 2026-09-05

    Scope: productFamilyContext, implementationCapabilities

  8. Deep Learning-Based Enhancement of Already Diagnostic-Quality MRI for Alzheimer's Disease Classification: Effects on Model Performance and Training Data Requirements

    Journal of Magnetic Resonance Imaging / U.S. National Library of Medicine - Published 2026-08-13 - Accessed 2026-09-05

    Scope: evidenceStudies, productFamilyContext

  9. Subtle Medical Compliance

    Subtle Medical, Inc. - Accessed 2026-10-25

    Scope: security

Research history

  1. K243250 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253775

SwiftMR

Airs Medical, Inc.

Authorized purpose: MRI image enhancement through noise reduction and sharpening; clinicians retain responsibility for final patient management decisions.

Modality
MRI
Anatomy
Whole Body
Decision
2026-03-26
FDA-cleared K253690

LungMaps

Siemens Healthineers AG

Authorized purpose: LungMaps processes one or more 2D lung MRI time series to support radiologist interpretation of ventilation and perfusion maps; it is not the sole source for diagnosis.

Modality
MRI
Anatomy
Chest/Lung
Decision
2026-06-15
FDA-cleared K260113

uMR Astra

Shanghai United Imaging Healthcare Co., Ltd.

Authorized purpose: uMR Astra is a diagnostic MR system for cross-sectional and spectroscopic imaging of the labeled head, body, and extremities.

Modality
MRI
Anatomy
Head; body; and extremities
Decision
2026-05-22

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history